[{"indications": "Indications\u00a0benign prostatic hyperplasia", "name": "DUTASTERIDE", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "6 Endocrine system", "6.4 Sex hormones", "6.4.2 Male sex hormones and antagonists", "Anti-androgens", "Dutasteride and finasteride", "DUTASTERIDE"], "cautions": "Cautions\u00a0\n(From Dutasteride and finasteride: British National Formulary)\nCautions\u00a0Dutasteride and finasteride decrease serum concentration of prostate cancer markers such as prostate-specific antigen; reference values may need adjustment. Both dutasteride and finasteride are excreted in semen and use of a condom is recommended if sexual partner is pregnant or likely to become pregnant. Women of childbearing potential should avoid handling crushed or broken tablets of finasteride and leaking capsules of dutasteride.; interactions: Appendix 1 (dutasteride)", "side-effects": "Side-effects\u00a0see notes above", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/127921.htm", "doses": ["500\u00a0micrograms daily, review treatment at 3\u20136 months and\r\nthen every 6\u201312 months (may require several months treatment before\r\nbenefit is obtained)"]}]